Stock Events

Stock Events

Amundi ESTOXX50 Dly -1X Inv UCITS -A 

€6.85
821
+€0.14+2.16%Friday 08:27

Statistics

Day High
6.85
Day Low
6.85
52W High
6.85
52W Low
6.85
Volume
-
Avg. Volume
-
Mkt Cap
9.93B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Expense Ratio

0.40%
0%
1%+
The annual fee that you pay to the fund company for managing your investment. The lower the expense ratio, the better. This is not an investment recommendation.

Earnings

Feb 3Expected
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Next
0.65
0.68
0.72
0.75
Expected EPS
0.6980300264
Actual EPS
N/A

Financials

14.44%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
17.42BRevenue
2.52BNet Income

Analyst Ratings

$39.70Average Price Target
The highest estimate is ⁦53.12⁩.
From 21 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LSK7.MU. It's not an investment recommendation.
NVIDIA
202
NVDA
Microsoft
195
MSFT
Amazon
176
AMZN
Apple
152
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Medtronic
MDT
Mkt Cap123.49B
Medtronic is a direct competitor in the medical devices sector, offering similar products in cardiology, endoscopy, and neuromodulation.
Abbott Laboratories
ABT
Mkt Cap183.77B
Abbott Laboratories competes with Boston Scientific in areas such as cardiovascular devices and diagnostics.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its medical devices segment, competes in the cardiovascular and orthopedics sectors similar to Boston Scientific.
Stryker
SYK
Mkt Cap111.95B
Stryker operates in the medical technology field, offering products that compete with Boston Scientific's neuromodulation and interventional specialties.
Zimmer Biomet
ZBH
Mkt Cap18.03B
Zimmer Biomet competes in the musculoskeletal healthcare sector, offering products that can be seen as alternatives to some of Boston Scientific's offerings.
Edwards Lifesciences
EW
Mkt Cap53.03B
Edwards Lifesciences is a competitor in the cardiovascular market, particularly in heart valves, where it competes directly with Boston Scientific.
Intuitive Surgical
ISRG
Mkt Cap152.62B
Intuitive Surgical competes with Boston Scientific in the surgical devices market, particularly with its robotic surgical systems.

Holdings

About

Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Show More
CEO
Michael F. Mahoney
Employees
59000
Country
United States
ISIN
FR0010424135
WKN
000A0MNT8

Listings

LSE
GB
0MRJ.LSE
LSE
GB
0HOY.LSE
PA
FR
BSX.PA
MI
IT
1BSX.MI

0 Comments

Share your thoughts

FAQs

What is Amundi ESTOXX50 Dly -1X Inv UCITS -A stock price today?▼
The current price of LSK7.MU is €6.85 EUR — it has increased by +2.16% in the past 24 hours. Watch Amundi ESTOXX50 Dly -1X Inv UCITS -A stock price performance more closely on the chart.
What is Amundi ESTOXX50 Dly -1X Inv UCITS -A stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Amundi ESTOXX50 Dly -1X Inv UCITS -A stocks are traded under the ticker LSK7.MU.
Is Amundi ESTOXX50 Dly -1X Inv UCITS -A stock price growing?▼
LSK7.MU stock has risen by +0.2% compared to the previous week, the month change is a +1.23% rise, over the last year Amundi ESTOXX50 Dly -1X Inv UCITS -A has showed a -9.38% decrease.
What is Amundi ESTOXX50 Dly -1X Inv UCITS -A market cap?▼
Today Amundi ESTOXX50 Dly -1X Inv UCITS -A has the market capitalization of 9.93B
When is the next Amundi ESTOXX50 Dly -1X Inv UCITS -A earnings date?▼
Amundi ESTOXX50 Dly -1X Inv UCITS -A is going to release the next earnings report on February 3, 2027.
What were Amundi ESTOXX50 Dly -1X Inv UCITS -A earnings last quarter?▼
LSK7.MU earnings for the last quarter are 0.65 EUR per share, whereas the estimation was 0.65 EUR resulting in a +0.43% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Amundi ESTOXX50 Dly -1X Inv UCITS -A revenue for the last year?▼
Amundi ESTOXX50 Dly -1X Inv UCITS -A revenue for the last year amounts to 17.42B EUR.
What is Amundi ESTOXX50 Dly -1X Inv UCITS -A net income for the last year?▼
LSK7.MU net income for the last year is 2.52B EUR.
How many employees does Amundi ESTOXX50 Dly -1X Inv UCITS -A have?▼
As of November 7, 2026, the company has 59,000 employees.
In which sector is Amundi ESTOXX50 Dly -1X Inv UCITS -A located?▼
Amundi ESTOXX50 Dly -1X Inv UCITS -A operates in the Health & Wellness sector.
When did Amundi ESTOXX50 Dly -1X Inv UCITS -A complete a stock split?▼
Amundi ESTOXX50 Dly -1X Inv UCITS -A has not had any recent stock splits.
Where is Amundi ESTOXX50 Dly -1X Inv UCITS -A headquartered?▼
Amundi ESTOXX50 Dly -1X Inv UCITS -A is headquartered in MARLBOROUGH, United States.